Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:ATXN2-STAT6

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: ATXN2-STAT6
	FusionPDB ID: 8434
	FusionGDB2.0 ID: 8434
		Hgene	Tgene
	Gene symbol	ATXN2	STAT6
	Gene ID	6311	6778
	Gene name	ataxin 2	signal transducer and activator of transcription 6
	Synonyms	ATX2\|SCA2\|TNRC13	D12S1644\|IL-4-STAT\|STAT6B\|STAT6C
	Cytomap	12q24.12	12q13.3
	Type of gene	protein-coding	protein-coding
	Description	ataxin-2spinocerebellar ataxia type 2 proteintrinucleotide repeat-containing gene 13 protein	signal transducer and activator of transcription 6STAT, interleukin4-inducedsignal transducer and activator of transcription 6, interleukin-4 inducedtranscription factor IL-4 STAT
	Modification date	20200313	20200329
	UniProtAcc	Q8WWM7 Main function of 5'-partner protein: FUNCTION: Involved in the regulation of stress granule and P-body formation. {ECO:0000269\|PubMed:23209657}.	P42226 Main function of 5'-partner protein: FUNCTION: Carries out a dual function: signal transduction and activation of transcription. Involved in IL4/interleukin-4- and IL3/interleukin-3-mediated signaling. {ECO:0000269\|PubMed:17210636}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000550104, ENST00000542287, ENST00000377617, ENST00000389153, ENST00000608853, ENST00000535949, ENST00000549455,	ENST00000300134, ENST00000454075, ENST00000537215, ENST00000538913, ENST00000543873, ENST00000556155,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	22 X 21 X 8=3696	42 X 21 X 17=14994
	# samples	25	46
	** MAII score	log2(25/3696*10)=-3.88596475675397 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(46/14994*10)=-5.02660763586348 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: ATXN2 [Title/Abstract] AND STAT6 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: ATXN2 [Title/Abstract] AND STAT6 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	ATXN2(111902466)-STAT6(57493223), # samples:1
Anticipated loss of major functional domain due to fusion event.	ATXN2-STAT6 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ATXN2-STAT6 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ATXN2-STAT6 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ATXN2-STAT6 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ATXN2-STAT6 seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF. ATXN2-STAT6 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. ATXN2-STAT6 seems lost the major protein functional domain in Tgene partner, which is a transcription factor due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	STAT6	GO:0045944	positive regulation of transcription by RNA polymerase II	8810328

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:111902466/chr12:57493223)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across ATXN2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across STAT6 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000389153	ATXN2	chr12	111902466	-	ENST00000300134	STAT6	chr12	57493223	-	4648	2684	31	3483	1150
ENST00000389153	ATXN2	chr12	111902466	-	ENST00000538913	STAT6	chr12	57493223	-	3856	2684	31	3483	1150
ENST00000389153	ATXN2	chr12	111902466	-	ENST00000543873	STAT6	chr12	57493223	-	3808	2684	31	3483	1150
ENST00000389153	ATXN2	chr12	111902466	-	ENST00000556155	STAT6	chr12	57493223	-	3715	2684	31	3483	1150
ENST00000389153	ATXN2	chr12	111902466	-	ENST00000537215	STAT6	chr12	57493223	-	3711	2684	31	3483	1150
ENST00000389153	ATXN2	chr12	111902466	-	ENST00000454075	STAT6	chr12	57493223	-	3691	2684	31	3483	1150
ENST00000608853	ATXN2	chr12	111902466	-	ENST00000300134	STAT6	chr12	57493223	-	5170	3206	253	4005	1250
ENST00000608853	ATXN2	chr12	111902466	-	ENST00000538913	STAT6	chr12	57493223	-	4378	3206	253	4005	1250
ENST00000608853	ATXN2	chr12	111902466	-	ENST00000543873	STAT6	chr12	57493223	-	4330	3206	253	4005	1250
ENST00000608853	ATXN2	chr12	111902466	-	ENST00000556155	STAT6	chr12	57493223	-	4237	3206	253	4005	1250
ENST00000608853	ATXN2	chr12	111902466	-	ENST00000537215	STAT6	chr12	57493223	-	4233	3206	253	4005	1250
ENST00000608853	ATXN2	chr12	111902466	-	ENST00000454075	STAT6	chr12	57493223	-	4213	3206	253	4005	1250
ENST00000377617	ATXN2	chr12	111902466	-	ENST00000300134	STAT6	chr12	57493223	-	5496	3532	162	4331	1389
ENST00000377617	ATXN2	chr12	111902466	-	ENST00000538913	STAT6	chr12	57493223	-	4704	3532	162	4331	1389
ENST00000377617	ATXN2	chr12	111902466	-	ENST00000543873	STAT6	chr12	57493223	-	4656	3532	162	4331	1389
ENST00000377617	ATXN2	chr12	111902466	-	ENST00000556155	STAT6	chr12	57493223	-	4563	3532	162	4331	1389
ENST00000377617	ATXN2	chr12	111902466	-	ENST00000537215	STAT6	chr12	57493223	-	4559	3532	162	4331	1389
ENST00000377617	ATXN2	chr12	111902466	-	ENST00000454075	STAT6	chr12	57493223	-	4539	3532	162	4331	1389

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000389153	ENST00000300134	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.000337494	0.9996625
ENST00000389153	ENST00000538913	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.000517845	0.9994822
ENST00000389153	ENST00000543873	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.000517043	0.99948287
ENST00000389153	ENST00000556155	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.000504787	0.99949515
ENST00000389153	ENST00000537215	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.000515176	0.9994848
ENST00000389153	ENST00000454075	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.00049384	0.9995061
ENST00000608853	ENST00000300134	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.00181872	0.99818134
ENST00000608853	ENST00000538913	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.002922062	0.99707794
ENST00000608853	ENST00000543873	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.002979901	0.99702007
ENST00000608853	ENST00000556155	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.002993607	0.99700636
ENST00000608853	ENST00000537215	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.003014938	0.996985
ENST00000608853	ENST00000454075	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.003007999	0.996992
ENST00000377617	ENST00000300134	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.001560871	0.99843913
ENST00000377617	ENST00000538913	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.002299953	0.99770004
ENST00000377617	ENST00000543873	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.002327876	0.99767214
ENST00000377617	ENST00000556155	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.002333455	0.9976666
ENST00000377617	ENST00000537215	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.002343929	0.9976561
ENST00000377617	ENST00000454075	ATXN2	chr12	111902466	-	STAT6	chr12	57493223	-	0.002332094	0.99766785

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ATXN2-STAT6

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
ATXN2	chr12	111902466	STAT6	chr12	57493223	2684	885	YNKETSPSFYFASSPQIENIQPFSAK
ATXN2	chr12	111902466	STAT6	chr12	57493223	3206	985	YNKETSPSFYFASSPQIENIQPFSAK
ATXN2	chr12	111902466	STAT6	chr12	57493223	3532	36	RWPGWRSLQRPARRSGRGGGGAAPGP

Top

Potential FusionNeoAntigen Information of ATXN2-STAT6 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

ATXN2-STAT6_111902466_57493223.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	HLA-A74:09	RSLQRPARR	0.9912	0.721	5	14
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	HLA-A74:03	RSLQRPARR	0.9912	0.721	5	14
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	HLA-A74:11	RSLQRPARR	0.9912	0.721	5	14
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B15:16	ASSPQIENI	0.9907	0.5196	11	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	HLA-A30:08	RSLQRPARR	0.9718	0.7407	5	14
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	HLA-A31:06	RSLQRPARR	0.9211	0.5412	5	14
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	HLA-A31:02	RSLQRPARR	0.8962	0.6943	5	14
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B52:01	FYFASSPQI	0.3178	0.9367	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B15:01	SSPQIENIQPF	0.9994	0.8632	12	23
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B13:01	SSPQIENIQPF	0.814	0.8108	12	23
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C04:14	YFASSPQI	0.8439	0.6924	9	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C15:06	ASSPQIENI	0.9992	0.7981	11	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	HLA-A31:01	RSLQRPARR	0.9914	0.6552	5	14
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C02:06	ASSPQIENI	0.4933	0.9447	11	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B51:07	FYFASSPQI	0.3392	0.8329	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C04:14	FYFASSPQI	0.3357	0.6741	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:05	FYFASSPQI	0.3332	0.9269	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:10	FYFASSPQI	0.3122	0.9292	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:80	FYFASSPQI	0.2887	0.909	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:67	FYFASSPQI	0.2887	0.909	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:13	FYFASSPQI	0.285	0.8858	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:19	FYFASSPQI	0.2839	0.5968	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:29	FYFASSPQI	0.2809	0.8962	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:46	FYFASSPQI	0.2467	0.8099	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C12:16	FYFASSPQI	0.2278	0.9625	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:95	FYFASSPQI	0.1895	0.5861	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:27	FYFASSPQI	0.1624	0.9234	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B15:05	SSPQIENIQPF	0.9759	0.7606	12	23
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C04:04	YFASSPQI	0.8915	0.7657	9	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C14:02	YFASSPQI	0.6901	0.9308	9	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C14:03	YFASSPQI	0.6901	0.9308	9	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C15:02	ASSPQIENI	0.9992	0.7367	11	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C15:05	ASSPQIENI	0.9991	0.848	11	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	HLA-A74:01	RSLQRPARR	0.9912	0.721	5	14
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B57:02	ASSPQIENI	0.988	0.8079	11	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	HLA-A30:01	RSLQRPARR	0.9776	0.8736	5	14
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C06:17	FYFASSPQI	0.3649	0.9931	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C06:02	FYFASSPQI	0.3649	0.9931	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C04:04	FYFASSPQI	0.3279	0.7072	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C03:67	FYFASSPQI	0.2989	0.98	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:02	FYFASSPQI	0.2887	0.909	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:22	FYFASSPQI	0.2839	0.7084	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:17	FYFASSPQI	0.2799	0.9455	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:01	FYFASSPQI	0.1973	0.5871	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C07:04	FYFASSPQI	0.1692	0.8976	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C06:08	FYFASSPQI	0.1346	0.9919	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C06:06	FYFASSPQI	0.0918	0.9863	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C14:02	FYFASSPQI	0.066	0.946	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C14:03	FYFASSPQI	0.066	0.946	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-C18:01	FYFASSPQI	0.0606	0.6467	8	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B15:27	SSPQIENIQPF	0.9994	0.8566	12	23
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B15:34	SSPQIENIQPF	0.9994	0.8632	12	23
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B15:33	SSPQIENIQPF	0.9994	0.8632	12	23
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B15:125	SSPQIENIQPF	0.9994	0.8632	12	23
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B15:53	SSPQIENIQPF	0.9985	0.8388	12	23
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B15:24	SSPQIENIQPF	0.9984	0.8387	12	23
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B15:12	SSPQIENIQPF	0.9961	0.8331	12	23
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B15:20	SSPQIENIQPF	0.9756	0.8466	12	23
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	HLA-B35:28	SSPQIENIQPF	0.9693	0.8464	12	23

Top

Potential FusionNeoAntigen Information of ATXN2-STAT6 in HLA II

ATXN2-STAT6_111902466_57493223.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0109	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0109	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0111	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0111	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0113	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0113	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0115	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0115	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0117	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0117	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0121	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0121	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0129	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0129	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0469	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0469	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0469	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0701	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0701	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0701	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0703	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0703	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0703	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0704	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0704	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0704	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0704	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0705	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0705	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0705	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0706	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0706	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0706	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0706	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0707	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0707	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0707	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0708	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0708	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0708	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0709	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0709	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0709	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0711	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0711	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0711	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0711	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0712	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0712	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0712	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0713	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0713	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0713	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0714	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0714	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0714	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0715	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0715	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0715	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0716	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0716	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0716	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0717	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0717	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0717	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0719	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0719	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0719	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0901	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0901	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0901	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0901	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0902	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0902	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0902	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0902	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0902	SFYFASSPQIENIQP	7	22
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0903	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0903	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0903	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0903	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0904	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0904	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0904	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0904	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0905	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0905	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0905	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0905	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0907	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0907	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0907	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0907	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0908	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0908	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0908	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0908	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0908	SFYFASSPQIENIQP	7	22
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0909	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0909	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0909	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-0909	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1002	ASSPQIENIQPFSAK	11	26
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1108	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1108	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1108	PGWRSLQRPARRSGR	2	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1111	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1114	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1114	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1119	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1119	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1119	PGWRSLQRPARRSGR	2	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1120	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1120	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1131	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1131	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1131	PGWRSLQRPARRSGR	2	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1145	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1145	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1164	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1164	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1164	PGWRSLQRPARRSGR	2	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1168	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1168	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1168	PGWRSLQRPARRSGR	2	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1172	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1172	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1172	PGWRSLQRPARRSGR	2	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1173	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1173	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1173	PGWRSLQRPARRSGR	2	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1179	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1179	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1182	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1186	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1186	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1186	PGWRSLQRPARRSGR	2	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1302	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1302	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1316	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1316	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1316	PGWRSLQRPARRSGR	2	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1323	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1323	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1329	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1329	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1329	PGWRSLQRPARRSGR	2	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1334	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1334	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1336	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1339	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1339	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1341	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1341	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1356	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1356	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1356	PGWRSLQRPARRSGR	2	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1363	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1373	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1373	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1374	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1374	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1382	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1382	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1382	PGWRSLQRPARRSGR	2	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1385	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1385	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1386	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1386	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1386	PGWRSLQRPARRSGR	2	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1396	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1397	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1397	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1399	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1399	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1402	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1403	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1403	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1430	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1430	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1430	PGWRSLQRPARRSGR	2	17
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1440	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1440	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1441	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1467	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1467	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1477	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1477	RWPGWRSLQRPARRS	0	15
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1489	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1494	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	3532	DRB1-1498	WPGWRSLQRPARRSG	1	16
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1502	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1502	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1508	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1508	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1511	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1511	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1514	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1514	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1515	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1515	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1519	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1519	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1526	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1526	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1527	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1527	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1527	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1529	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1529	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1530	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1530	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1531	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1531	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1534	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1534	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1534	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1534	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1538	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1538	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1539	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1539	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1544	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1544	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1547	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1547	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1601	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1601	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1601	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1602	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1602	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1602	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1602	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1603	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1603	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1603	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1604	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1604	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1604	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1605	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1605	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1605	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1605	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1607	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1607	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1607	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1607	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1608	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1608	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1608	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1609	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1609	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1610	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1610	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1611	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1611	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1611	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1611	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1612	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1612	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1612	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1612	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1614	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1614	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1614	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1614	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1616	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1616	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1616	ETSPSFYFASSPQIE	3	18
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB1-1616	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB3-0209	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB3-0209	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB3-0221	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB3-0221	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB5-0112	TSPSFYFASSPQIEN	4	19
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB5-0112	SPSFYFASSPQIENI	5	20
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB5-0112	PSFYFASSPQIENIQ	6	21
ATXN2-STAT6	chr12	111902466	chr12	57493223	2684	DRB5-0112	ETSPSFYFASSPQIE	3	18

Top

Fusion breakpoint peptide structures of ATXN2-STAT6

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
6982	PSFYFASSPQIENI	ATXN2	STAT6	chr12	111902466	chr12	57493223	2684

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
8779	SLQRPARRSGRGGG	ATXN2	STAT6	chr12	111902466	chr12	57493223	3532

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ATXN2-STAT6

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	6982	PSFYFASSPQIENI	-7.15543	-7.26883
HLA-B14:02	3BVN	6982	PSFYFASSPQIENI	-4.77435	-5.80965
HLA-B52:01	3W39	6982	PSFYFASSPQIENI	-6.80875	-6.92215
HLA-B52:01	3W39	6982	PSFYFASSPQIENI	-4.20386	-5.23916
HLA-A11:01	4UQ2	6982	PSFYFASSPQIENI	-7.5194	-8.5547
HLA-A11:01	4UQ2	6982	PSFYFASSPQIENI	-6.9601	-7.0735
HLA-A24:02	5HGA	6982	PSFYFASSPQIENI	-7.52403	-7.63743
HLA-A24:02	5HGA	6982	PSFYFASSPQIENI	-5.82433	-6.85963
HLA-B27:05	6PYJ	6982	PSFYFASSPQIENI	-3.28285	-4.31815
HLA-B44:05	3DX8	6982	PSFYFASSPQIENI	-5.91172	-6.94702
HLA-B44:05	3DX8	6982	PSFYFASSPQIENI	-4.24346	-4.35686
HLA-B14:02	3BVN	8779	SLQRPARRSGRGGG	-7.15543	-7.26883
HLA-B14:02	3BVN	8779	SLQRPARRSGRGGG	-4.77435	-5.80965
HLA-B52:01	3W39	8779	SLQRPARRSGRGGG	-6.80875	-6.92215
HLA-B52:01	3W39	8779	SLQRPARRSGRGGG	-4.20386	-5.23916
HLA-A11:01	4UQ2	8779	SLQRPARRSGRGGG	-7.5194	-8.5547
HLA-A11:01	4UQ2	8779	SLQRPARRSGRGGG	-6.9601	-7.0735
HLA-A24:02	5HGA	8779	SLQRPARRSGRGGG	-7.52403	-7.63743
HLA-A24:02	5HGA	8779	SLQRPARRSGRGGG	-5.82433	-6.85963
HLA-B27:05	6PYJ	8779	SLQRPARRSGRGGG	-3.28285	-4.31815
HLA-B44:05	3DX8	8779	SLQRPARRSGRGGG	-5.91172	-6.94702
HLA-B44:05	3DX8	8779	SLQRPARRSGRGGG	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of ATXN2-STAT6

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
ATXN2-STAT6	chr12	111902466	chr12	57493223	11	20	ASSPQIENI	TTGCCAGCTCTCCACAGATAGAGAACA
ATXN2-STAT6	chr12	111902466	chr12	57493223	12	23	SSPQIENIQPF	CCAGCTCTCCACAGATAGAGAACATCCAGCCAT
ATXN2-STAT6	chr12	111902466	chr12	57493223	5	14	RSLQRPARR	CAAGCCCTTCTTTCTACTTTGCCAGCT
ATXN2-STAT6	chr12	111902466	chr12	57493223	8	17	FYFASSPQI	CTTTCTACTTTGCCAGCTCTCCACAGA
ATXN2-STAT6	chr12	111902466	chr12	57493223	9	17	YFASSPQI	TCTACTTTGCCAGCTCTCCACAGA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
ATXN2-STAT6	chr12	111902466	chr12	57493223	0	15	RWPGWRSLQRPARRS	CATACAACAAGGAGACAAGCCCTTCTTTCTACTTTGCCAGCTCTC
ATXN2-STAT6	chr12	111902466	chr12	57493223	1	16	WPGWRSLQRPARRSG	ACAACAAGGAGACAAGCCCTTCTTTCTACTTTGCCAGCTCTCCAC
ATXN2-STAT6	chr12	111902466	chr12	57493223	11	26	ASSPQIENIQPFSAK	TTGCCAGCTCTCCACAGATAGAGAACATCCAGCCATTCTCTGCCA
ATXN2-STAT6	chr12	111902466	chr12	57493223	2	17	PGWRSLQRPARRSGR	ACAAGGAGACAAGCCCTTCTTTCTACTTTGCCAGCTCTCCACAGA
ATXN2-STAT6	chr12	111902466	chr12	57493223	3	18	ETSPSFYFASSPQIE	AGGAGACAAGCCCTTCTTTCTACTTTGCCAGCTCTCCACAGATAG
ATXN2-STAT6	chr12	111902466	chr12	57493223	4	19	TSPSFYFASSPQIEN	AGACAAGCCCTTCTTTCTACTTTGCCAGCTCTCCACAGATAGAGA
ATXN2-STAT6	chr12	111902466	chr12	57493223	5	20	SPSFYFASSPQIENI	CAAGCCCTTCTTTCTACTTTGCCAGCTCTCCACAGATAGAGAACA
ATXN2-STAT6	chr12	111902466	chr12	57493223	6	21	PSFYFASSPQIENIQ	GCCCTTCTTTCTACTTTGCCAGCTCTCCACAGATAGAGAACATCC
ATXN2-STAT6	chr12	111902466	chr12	57493223	7	22	SFYFASSPQIENIQP	CTTCTTTCTACTTTGCCAGCTCTCCACAGATAGAGAACATCCAGC

Top

Information of the samples that have these potential fusion neoantigens of ATXN2-STAT6

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
OV	ATXN2-STAT6	chr12	111902466	ENST00000377617	chr12	57493223	ENST00000300134	TCGA-25-1320-01A
OV	ATXN2-STAT6	chr12	111902466	ENST00000389153	chr12	57493223	ENST00000300134	TCGA-25-1320-01A

Top

Potential target of CAR-T therapy development for ATXN2-STAT6

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to ATXN2-STAT6

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to ATXN2-STAT6

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner	Gene	Disease ID	Disease name	# pubmeds	Source
Tgene	STAT6	C0018922	hemangiopericytoma	2	ORPHANET
Tgene	STAT6	C1266119	Solitary fibrous tumor	2	CTD_human;ORPHANET
Tgene	STAT6	C0011615	Dermatitis, Atopic	1	CTD_human
Tgene	STAT6	C0013604	Edema	1	CTD_human
Tgene	STAT6	C0018671	Head and Neck Neoplasms	1	CTD_human
Tgene	STAT6	C0018675	Head Neoplasms	1	CTD_human
Tgene	STAT6	C0027533	Neck Neoplasms	1	CTD_human
Tgene	STAT6	C0034069	Pulmonary Fibrosis	1	CTD_human
Tgene	STAT6	C0086196	Eczema, Infantile	1	CTD_human
Tgene	STAT6	C0151603	Anasarca	1	CTD_human
Tgene	STAT6	C0278996	Malignant Head and Neck Neoplasm	1	CTD_human
Tgene	STAT6	C0746787	Cancer of Neck	1	CTD_human
Tgene	STAT6	C0751177	Cancer of Head	1	CTD_human
Tgene	STAT6	C0887900	Upper Aerodigestive Tract Neoplasms	1	CTD_human
Tgene	STAT6	C4721507	Alveolitis, Fibrosing	1	CTD_human

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)